NCT07477626 2026-03-17
RADVAN
Sun Yat-sen University
Phase 3 Active not recruiting
Clinical Trials
31 trialsNCT05884398 2026-03-12
LIBERTAS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT04076059 2026-02-06
China ARCHES
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT02489318 2026-02-02
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT06205316 2026-01-20
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
Phase 3 Recruiting
NCT03767244 2026-01-16
PROTEUS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06235697 2026-01-13
ASCENDE-SBRT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT00309985 2025-12-11
CHAARTED
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT07260435 2025-12-03
Apa/Enza-short
Erasmus Medical Center
Phase 3 Recruiting
NCT06274047 2025-10-30
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT04934722 2025-10-01
KEYNOTE-991
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06320067 2025-09-26
STAMPEDE2
University College, London
Phase 3 Recruiting
NCT01715285 2025-02-04
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Janssen Research & Development, LLC
Phase 3 Completed
NCT06768255 2025-01-10
mCRPC
Fudan University
Phase 3 Not yet recruiting
NCT06276465 2024-12-20
PEACE8
UNICANCER
Phase 3 Recruiting
NCT06496581 2024-12-20
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
Phase 3 Recruiting
NCT02303327 2024-12-09
Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients
Sir Mortimer B. Davis - Jewish General Hospital
Phase 3 Active not recruiting
NCT01957436 2024-11-12
PEACE1
UNICANCER
Phase 3 Active not recruiting
NCT04916613 2024-09-26
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
UNICANCER
Phase 3 Recruiting
NCT05352178 2024-07-03
SPARKLE
Universitaire Ziekenhuizen KU Leuven
Phase 3 Recruiting
NCT00288080 2022-06-21
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT03119857 2021-08-18
Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14
Göteborg University
Phase 3 Unknown
NCT00104715 2021-02-21
Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
UNICANCER
Phase 3 Completed
NCT00079001 2020-05-12
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01978873 2016-05-04
SensiCab
Örebro University, Sweden
Phase 3 Unknown
NCT00685646 2015-10-16
ZAPCA
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 3 Completed
NCT00949962 2014-07-04
Post-operative or Early Salvage XRT and ADT for High Risk PCa
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT00242567 2014-05-07
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
Novartis
Phase 3 Completed
NCT00110162 2013-08-07
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Unknown